32nd Annual Meeting of the European Society for Hyperthermic Oncology

16–19 May 2018 • Berlin/Germany

32nd Annual Meeting of the European Society for Hyperthermic Oncology

16–19 May 2018 • Berlin/Germany

Congress details


Abstract submission


Welcome notes

Dear ESHO 2018 Participants,

Hyperthermia is a key therapy option for the treatment of solid tumors involving both the destruction of neoplastic cells via thermal ablation as well as the use of moderate temperatures to improve effectiveness of both radiation and chemotherapy.

Research and clinical application of hyperthermia techniques have been widely employed at the Charité - Universitätsmedizin for over three decades with the current Charité Hyperthermia Unit based at the Department of Radiation Oncology at our Virchow Campus. The Charité thus serves as a highly active hyperthermia-center, successfully securing substantial third-party funding whilst maintaining high scientific output. In addition, the establishment of national and international interdisciplinary collaborations within the fields of physics and biology as well as in numerous further clinical disciplines including gynecology, radiology and pediatric oncology is one of our foremost strengths. Current scientific activity focuses on technological, biological and translational research as well as the conduction of innovative clinical trials.  Such exploration is essential in order to achieve greater understanding of the underlying biological mechanisms involved in using hyperthermia for cancer treatment. Furthermore, research results generate additional evidence, which will inevitably lead to indication range extension for further tumor entities. This is particularly relevant in cases where standard treatments have proven unsatisfactory (e.g. abdominal tumors). 

It is therefore with great pleasure that we welcome the world’s leading hyperthermia experts to Berlin for the ESHO 2018. The conference has been organized in cooperation with the European Society for Radiotherapy & Oncology (ESTRO) and is endorsed by relevant national organizations as well as the European Cancer Organization (ECCO) and the European Society of Surgical Oncology (ESSO).

I am confident that the ESHO 2018 will serve as an excellent scientific exchange platform thus facilitating the advancement of hyperthermia research and improved clinical treatment.

Yours sincerely,

Karl Einhäupl

Charité - Universitätsmedizin Berlin

To foster innovations and to advance the speed of translation of those innovations to medical practice are core elements of the mission of the Berlin Institute of Health (BIH). We encourage the clinical and basic research community in Berlin to join forces to tackle this goal in an interdisciplinary and systemic approach. And – by establishing Berlin Health Innovations, the joint technology transfer initiative of BIH and Charité – we support inventors to deliver their ideas and concepts to markets and patients. ESHO and ESTRO are both societies with a translational mission very similar to the BIH mission. I am very happy that both societies choose Berlin for their annual meeting in 2018 and I wish the organizers and all attendees exciting days full of scientific interaction within their respective research communities and the local faculties.

Enjoy your annual meetings and

all the best,

Rolf Zettl
Chief Financial Officer